Michael Friedländer

Researcher Next ID · RN-004628

Researcher · Medicine

Sydney, Australia

Not currently recruitingFunding unknown

Research interests

Medicine

Biochemistry, Genetics and Molecular Biology

Ovarian cancer diagnosis and treatment

PARP inhibition in cancer therapy

BRCA gene mutations in cancer

Endometrial and Cervical Cancer Treatments

Cancer Treatment and Pharmacology

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1810858
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
JAMA · 2017 · https://doi.org/10.1001/jama.2017.7112
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1105535
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)60893-8
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.
Journal of Histochemistry & Cytochemistry · 1983 · https://doi.org/10.1177/31.11.6619538

No projects listed.